HSPB2 and neoplasm: More precisely, multivariate Cox models confirmed the unfavorable DFS of TaT1 patients under expressing HSPB2 (HR: 3.101; 95% CI: 1.134–8.484; p = 0.027) or HSPB3 (HR: 4.872; 95% CI: 1.322–17.96; p = 0.017), independently to tumor stage, grade, patient’s age and EORTC risk stratification (Table 2).